Monitor for peer reception of VEGA-3 data at ASCRS and any follow-up commentary from Viatris. A potential sNDA approval for presbyopia could be a future catalyst, but no new safety or efficacy surprises were revealed here.
Price Chart
Executive Summary
Opus Genetics announced that three abstracts, including full Phase 3 results from the VEGA-3 trial for presbyopia and data from MIRA-2 and LYNX-2 trials, will be presented at the ASCRS Annual Meeting. The data highlight clinical outcomes for phentolamine ophthalmic solution 0.75% across multiple vision conditions, with Viatris supporting an educational symposium on presbyopia management. This reinforces clinical momentum but does not contain new efficacy or safety data beyond prior disclosures.
Key Facts
- Three abstracts presented at ASCRS 2026, including full VEGA-3 Phase 3 results for presbyopia.
- VEGA-3 evaluated phentolamine ophthalmic solution 0.75% for distance-corrected near vision in presbyopia.
- MIRA-2 post-hoc analysis and LYNX-2 Phase 3 data on mesopic vision disturbances also presented.
- Viatris is funding an independent educational symposium on presbyopia, not a promotional event.
- No new clinical data or efficacy endpoints disclosed beyond what was expected.
Financial Impact
Limited immediate financial impact; supports future commercialization potential with Viatris.
Risk Factors
- No FDA approval yet for phentolamine in presbyopia or mesopic conditions.
- Clinical data presented are not new primary results but scheduled conference disclosures.
- Limited commercial traction to date despite large target population.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3271649 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $3.32 | awaiting T+60 | — | $3.46 (+4.22%) |
Oct 27, 2026 today | Insider Cluster | $3.32 | awaiting T+60 | — | $3.46 (+4.22%) |
Oct 23, 2026 4d ago | 144 | $3.32 | awaiting T+60 | — | $3.46 (+4.22%) |
Oct 21, 2026 6d ago | 8-K | $3.82 | awaiting T+60 | — | $3.46 (−9.42%) |
Oct 15, 2026 12d ago | 8-K | $3.84 | awaiting T+60 | — | $3.46 (−9.90%) |
Oct 15, 2026 12d ago | Press Release | $3.84 | awaiting T+60 | — | $3.46 (−9.90%) |
Sep 22, 2026 5w ago | Institutional Cluster | $5.16 | awaiting T+60 | — | $3.46 (−32.95%) |
Sep 11, 2026 6w ago | 8-K | $6.04 | awaiting T+60 | — | $3.46 (−42.72%) |
Sep 9, 2026 6w ago | 8-K | $5.73 | awaiting T+60 | — | $3.46 (−39.62%) |
Sep 2, 2026 7w ago | Press Release | $4.45 | awaiting T+60 | — | $3.46 (−22.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers